Procyrion Raises $30 Million Series D to Support Clinical Trials of its Aortix™ Percutaneous Blood Pump for Treating Heart Failure Patients

Press Release

Houston, TX (July 9, 2019) – Procyrion, Inc., a clinical-stage medical device company, today announced the completion of a $30 million Series D funding round led by a new investor, Bluebird Ventures. Returning investors include Fannin Partners, Scientific Health Development, the State of Texas, and an undisclosed strategic investor. The company is developing its Aortix™ system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function (cardiorenal syndrome). The investment will fund the company’s pilot study through the activities needed to support the submission of an FDA IDE application for its pivotal trial.  To date, Procyrion has raised more than $59 million in funding.  

“Of the more than 1 million patients per year in the U.S. admitted to the hospital with acute decompensated heart failure, 25–30% also have worsening renal function. These are typically the most difficult to treat patients with high mortality and rehospitalization rates. Today there is a major gap in effective therapies that are available to treat these critically ill patients, and as such, there is a significant opportunity to improve patient outcomes,” said Eric S. Fain, M.D., Procyrion’s president and chief executive officer. “The Aortix device is uniquely designed and positioned in the body to simultaneously decrease the workload of the heart and improve kidney function. These funds will allow us to make significant advances in our program, in particular, allowing us to assess the Aortix system’s ability to decongest cardiorenal patients in our pilot study.”

Thinner than a pencil and placed in less than ten minutes in a simple cath-lab procedure, Aortix™ offers hope for the large population of heart failure patients who are non-responders to medical therapy, but not ill enough to consider highly invasive and expensive surgical interventions like heart transplantation or LVAD implants. Placed in the descending thoracic aorta between the heart and renal arteries, Aortix is uniquely suited to treat cardiorenal patients. Aortix harnesses fluid entrainment to pump blood and increase total aortic velocity and flow without the need for a valve. Aortix disrupts the harmful cardiorenal cycle in two ways: above the pump, it rests the heart by reducing afterload, resulting in increased cardiac output and decreased cardiac work; and downstream, it provides increased blood flow to the kidneys resulting in increased urine output and a reduction in fluid overload.

"The Procyrion Aortix device provides an elegant solution for managing heart failure, a serious and difficult-to-treat problem,” said Jeff Bird, M.D., Ph.D., managing director of Bluebird Ventures.  “We are excited to work with this experienced team as they begin clinical testing."

In conjunction with their investment, Dr. Bird will join Procyrion’s board of directors.

Procyrion’s Aortix device is not approved for use or sale.



Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump initially for use in cardiorenal syndrome patients.  The device is designed to rest the heart by reducing afterload while simultaneously improving blood flow to vital organs.This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M.Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, and launched at Fannin Innovation Studio, is being developed to provide a minimally invasive treatment option for millions of chronic heart failure patients.  


Bluebird Ventures is an early-stage life sciences venture capital firm based in Silicon Valley.  Dr. Jeffrey Bird has been a venture investor for 20 years and was previously an executive at Gilead Sciences.  He serves on the boards of Forty Seven, Inc. and Portola Pharmaceuticals as well as several private companies.


PR Contact:

Dana Summers
Penman PR

Read More